But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Amryt marches ahead, but gene therapies from Krystal, Abeona and Castle Creek are heading towards data readouts.
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
At 90 days data from Krystal Biotech’s epidermolysis bullosa trial looked good. At 120 days there has been some backsliding.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Despite concerns about a missing patient, results from a tiny trial in epidermolysis bullosa boosted Krystal Biotech’s stock by 41%.